Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Merck
Mallinckrodt
Dow
Colorcon

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,470,359

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,470,359 protect, and when does it expire?

Patent 8,470,359 protects ELIGARD and is included in three NDAs.

This patent has sixty-seven patent family members in twenty-six countries.

Summary for Patent: 8,470,359
Title:Sustained release polymer
Abstract: A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.
Inventor(s): Dunn; Richard L. (Fort Collins, CO)
Assignee: QLT USA, Inc. (Willmington, DE)
Application Number:11/469,392
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,470,359

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021379-001 Jul 24, 2002 RX Yes Yes   Request a Trial   Request a Trial Y Y METHOD OF TREATING CANCER   Request a Trial
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021488-001 Feb 13, 2003 RX Yes Yes   Request a Trial   Request a Trial Y Y METHOD OF TREATING CANCER   Request a Trial
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021731-001 Dec 14, 2004 RX Yes Yes   Request a Trial   Request a Trial Y Y METHOD OF TREATING CANCER   Request a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,470,359

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 259217   Request a Trial
Austria 296088   Request a Trial
Austria 458469   Request a Trial
Australia 1331200   Request a Trial
Australia 2001292931   Request a Trial
Australia 2006241376   Request a Trial
Australia 2010201645   Request a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Johnson and Johnson
McKinsey
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.